Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
https://www.pdsbiotech.com/images/presentation/PDS_Biotech_Corporate_Presentation_SEPTEMBER2020.pdf
Had a sizable turnaround on Friday.
Low of 1.8400 closing at 2.34.
Their fund raising was over a week behind NSCI.
Still settling lower.
Lets see what their sp is doing in mid September
Have never held this share and it is obvious to anyone it is currently
extreme risk - Administration or large profits over the medium term.
What I do see is your constant repeated posting that this share is doomed.
It suggests an agenda.
So Hemogenyx are advised that a decision will be confirmed in the next few
days and it is likely to be positive. ( no suggestion yhis month or even year, as hypothetical)
They cannot announce that, it is still vague and either way - no RNS at 7.00am.
Early hours US East Coast Major US Pharmacutical senior executive advises Hemogenyx
that on US open they will announce collaboration as per previosly agrred terms.
RNS on US open.
So as the last poster said it does not have to be 7.00am GMT, it could cme at any time.
Quite a few small holdings being sold, fewer larger holding being bought.
Suspect a few will be regreting selling in a few weeks.
In these situations it is often forward selling Placing Shares.
We PI's are unaware there is a Placing underway to raise funds.
Many subscribing forward sell into Good News, which has raised the SP, above that
of the Placing Shares.
As the surplus shares are finally absorbed, the Company then anounces the Placing.
I have seen it happen with so many Companies.
It may not be the case with IQAI, we will soon see either way.
I see from their website Guarantor Loans Division 32,600 customers
owing £105.5 million
Haven't a clue what is going on.
I see two theories - Manipulation with HSBC picking up cheap stock
or Forward Selling of Placing shares, issued at or only a little above 5 pence.
How about HSBC picking up cheap stock from Forward Sellers - both theories being correct.
Lucan a Takeover is a possibility, it may of course never happen.
You seem to imply it would not happen as Vlad is the only asset.
For your information is Silicon Valley there is an expression "Aquihire"
A company like Google buys a startup for a huge sum, a year or two after founded.
They have no interest in the startups business model, however they want the best of the
1-3 software developers.
On aquisition, retain the targetted founder, heading up a new project for Google - he has
millions in his pocket, excellent salary and options on Google stock.
Let the original startup project wither away.
In Hemogenyx 's case they not only want Vlad, they also want what has been produced, a
much more powerful proposition - suggesting a takeover more likely.
Maybe a year down the line.
Are you serious.
MM drop the price to hoover up shares and restricting buying as much as they can.
Then after the close you see the delayed buys appear.
The agreement with Eli Lilly, with the financials is due any day - then look at the sp.
There could be a Takeover, maybe not this year.
At the end of the day if Vlad accepted an offer, he would no longer have the
distraction of running a quoted company.
With licencing from majors it doesn't really matter, we should see a significant uplift
in the sp over a longer timeframe than would be the case if a bid came.
A poster on Twitter has observed that Takeda, a $56.6 Billion Company is
raising $7 Billion in loan notes.
On 8th January 2018 Takeda bought the British pharmaceutical Shire for $62 Billion.
By all accounts there were at least two other potential counter bidders and Takeda had
to raise their offer several times to clinch the deal.
There is nothing as yet to suggest they are looking at Hemogenyx, but it certainly looks like
they are preparing for an acquisition.